1. Begg MD, Panageas KS, Mitchell-Lewis D, Bucklan RS, Phelan JA, Lamster IB. Oral lesions as markers of severe immunosuppression in HIV-infected homosexual men and injection drug users. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 82: 276-283.
2. Begg MD, Lamster IB, Panageas KS, Mitchell-Lewis D, Phelan JA, Grbic JT. A prospective study of oral lesions and their predictive value for progression of HIV disease. Oral Dis 1997; 3: 176-183.
3. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. A decision analysis of prophylactic mastectomy and oophorectomy in BRCA1 or BRCA2 positive patients. J Clin Oncol 1997; 16: 979-985.
4. Wickens JC, Whelan RL, Allendorf JD, Donahue J, Buxton E, McKee A, Panageas KS, Gleason N, Lee S, Bessler M. Wound tensile strength and contraction rate are not affected by laparotomy or pneumoperitoneum. Surg Endosc 1998; 12: 1166-1170.
5. Begg MD, Panageas KS. Interval estimation of the common odds ratio from k(2x2) tables under cluster sampling. Stat Med 1999; 18: 1087-1100.
6. Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high risk node positive breast cancer: a phase II study. J Clin Oncol 1999; 17: 1118-1126.
7. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schucter LM, Ernstoff MS, Houghton AN, Kirkwood JM. Phase III multicenter randomized trial of the Dartmouth regimen versus Dacarbazine in patients with metastatic melanoma, J Clin Oncol 1999; 77: 2745-2751.
8. Nasi LN, Lieberman P, Busam K, Prieto V, Panageas KS, Lewis JJ, Houghton AN, Chapman PB. Intradermal injection of granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma. Cytokines Cell Mol Ther 1999; 5: 139-144.
9. Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas KS, Moynahan M, Houghton A, Norton L, Livingston P. Vaccination of high risk breast cancer patients with mucin-1 keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 1999; 6: 1693-1701.
10. Wang S, Bartido S, Yang G, Qin J, Moroi Y, Panageas KS, Lewis JL, Houghton AN. A role for a melanosome transport signal in accessing the MHC class II presentation pathway and eliciting CD4+ T cell responses. J Immunol 1999; 163: 5820-5826.
11. Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN, Williams L, Israel RJ, Livingston PO. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-KLH+QS21 vaccine: a dose-response study. Clin Cancer Res 2000; 6: 874-879.
12. Lewis JJ, Janetzki S, Schaed S, Panageas KS, Wang S, Williams L, Meyers M, Butterworth L, Livingston PO, Chapman PB, Houghton AN. Evaluation of CD8+ T cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Intl J Cancer 2000; 87: 391-398.
13. Deckert PM, Jungbluth A, Montalto N, Clark MA, Finn RD, Williams Jr C, Richards EC, Panageas KS, Old LJ, Welt S. Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts. Intl J Cancer 2000; 87: 382-390.
14. Mazumdar M, Fazzari M, Panageas KS. A standardization method to adjust for the effect of patient selection in phase II clinical trials. Stat Med 2001; 20: 883-892.
15. Chapman PB, Morrisey D, Panageas KS, Williams L, Lewis JL, Dantis L, Houghton AN, Livingston PO. Vaccination with a bivalent GM2 and GD2 ganglioside vaccine: A trial comparing doses of GD2-KLH, Clin Cancer Res 2000: 4658-4662.
16. Seidman AD, Fornier M, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero VN, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, Cristofanilli M, Rivera E, Hortobagyi G, Norton L, Hudis CA. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19: 2587-2595.
17. Ballangrud AM, Yang WH, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, Ma D, Bander NH, Scheinberg DA, Sgouros G. Response of LNCaP spheroids following treatment with alpha-particle-emitter (213Bi)-labeled anti-PSMA antibody (J591), Cancer Res 2001; 61: 2008-2014.
18. Gilewski T, Ragupathi G, Bhuta S, Panageas KS, Chin J, Norton L, Houghton AN, Livingston PO, Danishefsky S. Immunization of metastatic breast cancer patients with a fully synthetic globo-H conjugate- A phase I trial. Proc Natl Acad Sci 2001; 98: 3270-3275.
19. Bilsky MH, Boland PJ, Panageas KS, Woodruff JM, Brennan MF, Healey JH. Intralesional resection of primary and metastatic sarcoma involving the spine: outcome analysis of 59 patients. Neurosurg 2001; 49:1277-1286.
20. Gonen M, Panageas KS, Larson S. Statistical issues in the analysis of diagnostic imaging experiments with multiple observations per patient. Radiology, 2001; 221:763-767.
21. Hwu W-J, Raizer J, Panageas KS, Lis E. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol 2001; 2: 634-635.
22. Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res 2001; 7: 3934-3941.
23. Musselli C, Ragupathi G, Gilewski T, Panageas KS, Spinat Y, Livingston PO. Re-Evaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Intl J Cancer 2002; 97:660-667.
24. Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidman AD. Assessment of molecular markers of clinical sensitivity to single agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002; 20: 2319-2326.
25. Schaed SG, Klimek VM, Panageas KS, Musselli CM, Butterworth L, Hwu WJ, Livingston PO, Williams L, Lewis JJ, Houghton AN, Chapman PB. T cell responses against tyrosinase 368-376 (370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, GM-CSF, and QS-21 as immunological adjuvants. Clin Cancer Res 2002; 8: 967-972.
26. Hwu W-J, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, Williams LJ, Quinn CJ, Houghton AN. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol 2002; 20: 2610-2615.
27. Chapman PB, Panageas KS, Williams L, Wolchok JD, Livingston PO, Quinn C, Hwu WJ. Clinical results using biochemotherapy as a standard of care in advanced melanoma. Melanoma Res 2002; 12: 381-387.
28. Hazan C, Melzer K, Panageas KS, Li E, Kamino H, Kopf A, Cordon-Cardo C, Osman I, Polsky D. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. Cancer 2002; 95: 634-40.
29. Panageas KS, Smith A, Gonen M, Chapman PB. An optimal two‑stage phase II design utilizing complete and partial response information separately. Control Clin Trials, 2002; 23: 355-366.
30. Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 2002; 9: 637-645.
31. Modi S, Panageas KS, Bach A, Weinstock N, Dougherty J, Cramer L, Hudis C, Norton L, Seidman AD. Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. J Clin Oncol 2002; 20: 3665-3673.
32. Schrag D, Panageas KS, Riedel E, Cramer LD, Guillem JG, Bach PB, Begg CB: Surgeon volume compared to hospital volume as a predictor of outcome following rectal cancer surgery. Ann Surg 2002; 235: 583-592.
33. Polsky D, Melzer K, Hazan C, Panageas KS, Busam K, Drobnjak M, Kamino H, Spira JG, Kopf AW, Houghton A, Cordon-Cardo C, Osman I. HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst 2002; 94: 1803-1806.
34. Satagopan JM, Panageas KS. A statistical perspective on gene expression data analysis. Stat Med 2003; 22: 482-499.
35. Prabhu VC, Bilsky MH, Jambekhar K, Panageas KS, Boland PJ, Lis E, Heier L, Nelson PK. Current results of preoperative embolization for metastatic spinal neoplasms. J Neurosurg 2003; 98 (2 Suppl):156-164.
36. Gyorki DE, Busam K, Panageas KS, Brady MS, Coit DG. Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. Ann Surg Oncol 2003; 10: 403-407.
37. Sgouros G, Squeri S, Ballangrud AM, Kolbert KS, Teitcher JB, Panageas KS, Finn RD, Divgi CR, Larson SM, Zelenetz AD. Patient-specific, 3-D dosimetry in non-hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med 2003; 44: 260-268.
38. Schrag D, Panageas KS, Riedel E, Hsieh L, Bach PB, Guillem JG, Begg CB. Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J Surg Oncol 2003; 83: 68-78.
39. Panageas KS, Begg MD, Grbic JT, Lamster IB. Analysis of multiple 2x2 tables with site-specific periodontal data. J Dent Res 2003; 82: 514-517.
40. Hwu WJ, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, Williams LJ, Quinn CJ, Foster T, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003; 21: 3351-3356.
41. Panageas KS, Schrag D, Riedel E, Bach PB, Begg CB. The effect of clustering on the association of procedure volume and surgical outcomes. Ann Intl Med 2003;139: 658-665. [Accompanied by editorial]
42. Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, Finn RD, Larson SM, O'Reilly RJ, Scheinberg DA, Jurcic JG. Cytoreduction with Iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant 2003; 32: 549-556.
43. Brogi E, Robson M, Panageas KS, Casadio C, Marie-Ljung B, Montgomery L. Ductal lavage in patients undergoing mastectomy for mammary carcinoma: a correlative study. Cancer 2003; 98: 2170-2176.
44. Sandberg DI, Bilsky MH, Kushner BH, Souweidane MM, Kramer K, Laquaglia MP, Panageas KS, Cheung NK. Treatment of spinal involvement in neuroblastoma patients. Pediatric Neurosurg 2003; 39: 291-298.
45. Cestari DM, Weine DM, Panageas KS, Segal AZ, DeAngelis LM. Stroke in patients with cancer: incidence and etiology. Neurology 2004; 62: 2025-2030.
46. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis, CA. Phase II Study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab- based treatments. Clin Cancer Res 2004; 10: 4062-4067.
47. Dang CT, D'Andrea GM, Moynahan ME, Dickler MN, Seidman AD, Fornier M, Robson ME, Theodoulou M, Lake D, Currie VE, Hurria A, Panageas KS, Norton L, Hudis CA. Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clin Cancer Res 2004; 10: 5754-5761.
48. Janetzki S, Schaed S, Blachere NB, BenPorat L, Houghton AN, Panageas KS. Evaluation of ELISPOT assays: Influence of method and operator on variability of results. J Immunol Methods 2004; 291: 175-183.
49. King TA, Gemignani ML, Li W, Giri DD, Panageas KS, Bogomolniy F, Arroyo C, Olvera N, Robson ME, Offit K, Borgen PI, Boyd J. Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers. Cancer Res 2004; 64: 5051-5053.
50. Kattan MW, Giri D, Panageas KS, Hummer A, Cranor M, VanZee KJ, Hudis CA, Norton L, Borgen PI, Tan LK. A tool for predicting breast cancer mortality in women who do not receive adjuvant therapy. Cancer 2004; 101:2509-2515.
51. Chang DZ, Panageas KS, Osman I, Polsky D, Busam K, Chapman PB. Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med 2004; 2:46.
52. Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan L, Hudis CA. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 2005; 90:157-163.
53. Raizer JJ, Koutcher JA, Abrey LA, Panageas KS, DeAngelis LM, Lis E, Xu S, Zakian K. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neurooncol 2005; 71:173-180.
54. Hale E, Stein J, Ben-Porat L, Panageas KS, Eichenbaum MS, Marghoob AA, Osman I, Kopf AW, Polsky D. Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic nevi-results from the NYU-LCMN registry. Br J Dermatol 2005; 152: 512-517.
55. Jimenez RE, Panageas KS, Busam KJ, Brady MS. Prognostic implications of multiple lymphatic basin drainage in patients with truncal melanoma. J Clin Oncol 2005;23:518-524.
56. Hawkins WG, Busam KJ, Ben Porat L, Panageas KS, Coit DG, Gyorki DE, Linehan DC, Brady MS. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Onc 2005; 12: 207-213.
57. Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, VanPoznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest, 2005; 2396):483-487.
58. Hurria, A, Brogan K, Panageas KS, Pearce C, Norton L, Jakubowski A, Zauderer M, Howard J, Hudis C. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2005; 92:151-156.
59. Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer 2005; 6:55-60.
60. Hwu, WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ, Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 2005; 103:2590-2597.
61. Omuro AMP, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, DeAngelis LM, Abrey LE. Delayed neurotoxicity in primary central nervous system lymphoma Arch Neurol, 2005; 62:1595-1600.
62. Mikhail M, Velasquez E, Shapiro R, Berman R, Pavlick A, Sorhaindo L, Spira J, Mir C, Panageas KS, Polsky D, Osman I. PTEN Expression in Melanoma: Relationships with Patients' Survival, Bcl-2 Expression, and Proliferation. Clin Cancer Res, 2005; 11(14): 5153-5157.
63. Hurria A, Brogan K, Panageas KS, Jakubowski A, Zauderer M, Norton L, Howard J, Hudis C. Change in Cycle 1 to Cycle 2 Hematologic Counts Predicts Toxicity in Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy. Drugs Aging, 2005; 22(8):709-15.
64. Hurria A, Gupta S, Zauderer M, Zuckerman E, Cohen HJ, Muss H, Panageas KS, Holland J, Saltz L, Kris MG, Noy A, Gomez J, Rodin M, Jakubowski A, Hudis C, Pearce C, Kornblith A. Developing a Cancer-Specific Geriatric Assessment (CSGA): A Feasibility Study. Cancer, 2005;104(9): 1998-2005.
65. Panageas KS, Elkin EB, DeAngelis LM, Ben Porat L, Abrey LE. Trends in survival from Primary Central Nervous System Lymphoma 1975-1999: a population-based analysis. Cancer, 2005; 104(11):2466-2472.
66. Hurria A, Hurria A, Brogan K, Panageas KS, Pearce C. Norton L, Jakubowski A, Howard J, Hudis C, Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. Drugs Aging, 2005; 22(9): 785-91.
67. Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Variates of survival in metastatic uveal melanoma. J Clin Oncol, 2005; 23(31):8076- 8080.
68. Ferrone CR, Ben Porat L, Panageas KS, Berwick M, Halpern AC, Patel A, Coit DG. Multiple Primary Melanomas: Clinicopathologic Features and Risk Factors in 385 atients. JAMA, 2005; 294(13):1647-54.
69. Fornier MN, Modi S, Panageas KS, NortonL, Hudis C. incidence of Chemotherapy-nduced long-term amenorrhea in breast cancer patients age 40 years and younger after adjuvant anthracycline and taxane. Cancer, 2005; 104(8): 1575-9.
70. VanPoznak C, Cross SS, Saggese M, Hudis C, Panageas KS, Norton L, Coleman RE, Holen I. Expression of Osteoprotegerin (OPG), TNF-related apoptosis inducing ligand (TRAIL) and receptor activator of nuclear factor KB ligand (RANKL) in human breast tumors. J Clin Pathol, 2006; 59(1):56-63.
71. Ben-Porat L, Panageas KS, Hanlon C, Patel A, Halpern A, Houghton AN, Coit D. Estimates of stage-specific survival are altered by the changes in the 2002 AJCC staging for melanoma Cancer, 2006;106(1):163-71.
72. Lassman AB, Abrey LE, Shah G, Panageas KS, Begemann M, Malkin MG, Raizer JJ. Systemic High-dose Intravenous Methotrexate for Central Nervous System Metastases, Journal of Neuro-Oncology, 2006; 78(3):261.
73. Elkin EB, Hurria A, Mitra N. Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J. Clin Oncol, 2006; 24(18):2757-64.
74. Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, Williams LJ, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Phase II study of temozolomide plus pegylated interferon alfa-2b for metastatic melanoma. Cancer, 2006; 106(11): 2445-51.
75. Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, Witmer M, vanGorp WG, Fornier M, D'Andrea, Moasser M, DangC, VanPoznak C, Hurrua A, Holland J. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J American Ger Soc, 2006; 54(6):925-31.
76. Lamanna N, Kalaycio M, Maslak P, Jurcic J, Heaney M, Brentjens R, Zelenetz AD, Horgan D, Gencarellli A, Panageas KS, Scheinberg DA, Weiss MA. Pentostatin, cyclophosphamide and rituximab (PCR) has similar activity but may be better tolerated than fludarabine, cyclophosphamide and rituximab (FCR) in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol, 2006; 24(10): 1578-81.
77. Schrag D, Earle C, Xu F, Panageas KS, Yabroff KR, Bristow RE, Trimble EL, Warren JL, Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian resection. J. Natl Cancer Inst, 2006; 98(3):163-71.
78. Hurria A, Hurria A, Zuckerman E, Panageas KS, Fornier M, D'Andrea G, Dang C, Moasser M, Robson M, Seidman A, Currie V, VanPoznak C, Theodoulou M, Lachs M, Hudis C. A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. J American Ger Soc, 2006; 54(7):1119-24.
79. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC. YKL-40 and MMP-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res, 2006; 12(19):5698-704.
80. Tuma R, Alymyroudis N, Shohn S, Panageas, KS, Rice R, Galinkin D, Blain M, Montefusco M, Pamer E, Nimer S, Kewalramani T. The serum Il-2: Il-6 ratio reliably distinguishes infectious from non-infectious causes of fever during autologous stem cell transplantation, Cytotherapy 2006; 8(4):327-34.
81. Panageas KS, Schrag D, Localio AR, Venkatraman ES, Begg CB. Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size. Stat Med, in press.
82. Hurria A, Fleming MT, Baker SD, Kelly WK, Cutchall K, Panageas KS, Caravelli J, Yeung H, Kris M, Gomez J, Miller V, D'Andrea G, Scher HI, Norton L, Hudis C. Pharmacokinetics and toxicity of weekly docetaxel in the elderly, Clin Cancer Res, in press.
83. Abrey LE, Panageas KS. Identifying and Addressing Barriers to the Delivery of Optimal Therapy for PCNSL in the Broader Community, Leukemia and Lymphoma, in press.
84. Fornier MN, Seidman AD, Lake D, D'Andrea G, Bromberg J, Robson M, VanPoznak C, Panageas KS, Atienza M, Norton L, Hudis C. Increased dose-density is feasible: A pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10 or 11 day intervals with filgrastim support in women with breast cancer, Clin Cancer Res, in press.
85. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehata M, DeAngelis LM. The Memorial Sloan-Kettering Cancer Center prognostic model for primary central nervous system lymphoma. J Clin Oncol, in press.
86. Yuan J, Gallardo H, Rasalan T, Ranganathan R, Wang J, ZHang Y, Panageas K, Stan R, Young J, Houghton A, Wolchok J. In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring. Cytotherapy, 2006; 8(5):498-508.
